Clinical Trial Update: Durvalumab and Tremelimumab in Resectable HCC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating durvalumab and tremelimumab in resectable hepatocellular carcinoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Durvalumab (durvalumab)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: University Health Network, Toronto | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: RECRUITING